Date: 2015-04-29
Type of information: Series B financing round
Company: CRISPR Therapeutics (Switzerland)
Investors: SR One (UK) Celgene (USA - NJ) New Enterprise Associates (NEA) (USA - MD) Abingworth (UK) Versant Ventures (USA - CA)
Amount: $ 89 million
Funding type: series B financing round
Planned used:
Others: * On April 29, 2015, CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, announced the closing of a Series A and Series B financing totaling $ 89 million, including $ 35 million of new funding in the Series A and $ 29 million in the Series B. The oversubscribed Series A and Series B financings were led by strategic investors, SR One and Celgene Corporation, respectively, and included new investors New Enterprise Associates (NEA) and Abingworth, alongside the Company’s founding investor, Versant Ventures. CRISPR Therapeutics has also announced changes to its Board of Directors. Simeon George, SR One, Ali Behbahani, NEA, and Kurt von Emster, Abingworth, will be joining Brad Bolzon, Tom Woiwode, and Chief Executive Officer, Rodger Novak. * On April 24, 2014, CRISPR Therapeutics announced it has raised $25 million in a series A investment from Versant Ventures. The company also announced a founding team comprising high-profile experts in diverse fields of science including CRISPR-Cas9, genome editing, stem cell biology, advanced drug delivery technologies, RNA interference and gene silencing.
Therapeutic area: Genetic diseases - Rare diseases